People: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

23 Dec 2014
Price Change (% chg)

CHF-1.20 (-1.28%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Reinhardt, Joerg 

Brief Biography

Mr. Joerg Reinhardt, Ph.D. has been Chairman of the Board of Directors of Novartis AG since August 2013. He is Chairman of the Chairman's Committee. Dr. Reinhardt previously served as chairman of the board of management and the executive committee of Bayer HealthCare. Prior to that, he served as Chief Operating Officer of Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. He also served as Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010; as a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004; and as a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013. He is currently a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Dr. Reinhardt graduated with a Ph.D. in pharmaceutical sciences from Saarland University in Germany. He joined Sandoz Pharma Ltd. in 1982 and held various positions including Head of Development. Following the merger that created Novartis in 1996, Dr. Reinhardt became Head of Preclinical Development and Project Management at Novartis, and assumed the position of Head of Pharmaceutical Development in 1999. His leadership, Global and Industry experience include being former chairman of global healthcare company; former COO of Novartis and former Chairman of Novartis research institution; former board member of biotechnology company; former board member of global supplier for pharmaceutical, healthcare, and life sciences industries; member of global non-profit representing pharmaceutical industry.

Basic Compensation

Total Annual Compensation, CHF Long-Term Incentive Plans, CHF All Other, CHF Fiscal Year Total, CHF
1,741,690 -- 159,124 1,900,810

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Joerg Reinhardt


Joseph Jimenez


Ulrich Lehner


Harry Kirsch


Peter Kornicker


Felix Ehrat

As Of 30 Dec 2013
Search Stocks